Indetek's IDT-003 Gel Phase I Clinical Trial Officially Kicked-off and Low Dose Group Subjects Enrolment Completed

Indetek Lab's IDT-003 Gel Receives Clinical Trial Notification from Center for Drug Evaluation, NMPA

Indetek Lab’s IND application for IDT-003 Gel, an innovative drug for melasma treatment, was formally accepted by CDE

Indetek’s ILDS® transdermal drug delivery technology platform has been granted its first invention patent.

Indetek’s Employee Awarded for 2023 Exceptional Innovation Award in Minhang District, Shanghai

Phase III clinical trial of Indetek' IDT-001 has successfully commenced at the Third Xiangya Hospital of Central South University.

Indetek Laboratory, a biotech specializing in innovative dermatological drug development, has completed a pre-Series A financing round worth tens of millions of RMB, accelerating the advancement of new drugs in the field of dermatology.